Navigating Univera Healthcare Skyrizi Prior Authorization with Klivira
Klivira automates the complex process of obtaining Univera Healthcare Skyrizi prior authorization, ensuring faster approvals and reduced administrative burden for your practice.
Biologic therapies like Skyrizi (risankizumab) often require stringent prior authorization (PA) from payers such as Univera Healthcare. This necessitates a deep understanding of specific formulary tiers, clinical criteria, and submission pathways. For revenue cycle directors and prior authorization coordinators, efficient management of these workflows is critical to patient access and financial health.
Univera Healthcare's Formulary Approach to Skyrizi (Risankizumab)
As an IL-23 inhibitor indicated for conditions like plaque psoriasis, psoriatic arthritis, and Crohn's disease, Skyrizi typically falls within a specialty tier on most formularies, including Univera Healthcare's. This designation often means it is subject to prior authorization requirements, step therapy protocols, and quantity limits to ensure appropriate utilization and cost management. Understanding Univera's specific formulary guidance for risankizumab is the first step in a successful PA submission.
Common Prior Authorization Hurdles for Skyrizi with Univera Healthcare
- **Step Therapy Requirements:** Documentation of trial and failure (or contraindication) of preferred formulary alternatives.
- **Clinical Criteria:** Evidence of a confirmed diagnosis (e.g., plaque psoriasis, psoriatic arthritis, Crohn's disease) and disease severity.
- **Quantity Limits (QL):** Adherence to prescribed dosing and frequency, often monitored through pharmacy claims.
- **Reauthorization Protocols:** Submission of updated clinical information to justify continued medical necessity beyond initial approval periods.
- **PBM and Specialty Pharmacy Routing:** Specific requirements for drug fulfillment through a designated PBM and specialty pharmacy network.
Navigating Univera Healthcare's PBM and Specialty Pharmacy Network
Univera Healthcare, like many payers, partners with a Pharmacy Benefit Manager (PBM) to manage its prescription drug benefits, particularly for high-cost specialty medications like Skyrizi. This often dictates that Skyrizi prescriptions must be filled through a specific specialty pharmacy within the PBM's network. Klivira's platform is designed to identify and integrate with these specific routing requirements, ensuring that PA approvals are correctly linked to the designated dispensing channels.
Streamlining Univera Healthcare Skyrizi Prior Authorization with Klivira
Klivira automates the end-to-end prior authorization process for Skyrizi with Univera Healthcare, from initiation to approval. Our platform leverages SMART on FHIR integrations with leading EMRs to extract necessary patient data, auto-populates X12 278 transactions, and intelligently routes submissions via ePA or payer portals. This reduces manual data entry, minimizes errors, and accelerates the entire PA lifecycle, freeing your staff to focus on patient care.
Proactive Management of Skyrizi Denials and Appeals
Despite best efforts, denials can occur. Klivira's system provides real-time status tracking and alerts for Univera Healthcare Skyrizi prior authorization requests, allowing for prompt intervention. In the event of a denial, our platform supports efficient appeals management by organizing clinical documentation and facilitating rapid resubmission, helping to overturn denials and maintain patient access to critical therapies.
Frequently asked questions
What are the primary prior authorization criteria for Skyrizi under Univera Healthcare?
Univera Healthcare typically requires a confirmed diagnosis for an FDA-approved indication (e.g., plaque psoriasis, psoriatic arthritis, Crohn's disease), documentation of disease severity, and often a trial and failure of conventional or preferred therapies before approving Skyrizi.
Does Univera Healthcare require specific step therapy for Skyrizi (risankizumab)?
Yes, it is common for Univera Healthcare to implement step therapy protocols for specialty biologics like Skyrizi. This means patients may need to demonstrate an inadequate response or intolerance to other formulary-preferred agents before Skyrizi will be approved.
How does Klivira integrate with EMRs for Univera Healthcare Skyrizi PA submissions?
Klivira utilizes SMART on FHIR and other secure integration methods to connect directly with your EMR system. This allows for automated extraction of relevant patient data for Univera Healthcare Skyrizi prior authorization forms, minimizing manual data entry and ensuring data accuracy.
Can Klivira help manage Skyrizi reauthorizations for Univera Healthcare members?
Absolutely. Klivira's platform tracks the approval expiry dates for Univera Healthcare Skyrizi prior authorizations and proactively prompts for reauthorization submissions, ensuring continuity of care without interruption due to lapsed approvals. This includes compiling necessary updated clinical documentation.
Does Univera Healthcare utilize a specific PBM for Skyrizi prescriptions?
While Klivira cannot confirm specific PBM partnerships for Univera Healthcare, most payers leverage a PBM to manage specialty drug benefits. Our system is designed to adapt to various PBM requirements and specialty pharmacy networks, ensuring proper routing regardless of Univera's specific partner.
Related coverage
Ready to automate prior auth for this plan?
See how Klivira automates prior authorizations for your team.
Request a demo